Digene launches HBV (hepatitis B virus) test for research use:
This article was originally published in Clinica
Digene has launched a DNA test for hepatitis B based on its Hybrid Capture technology for use in measuring the effects of antiviral therapies in US patients. HBV is the second most common chronic infectious disease in the world, affecting 350 million people and killing one million every year. The test, which is already used outside the US, detects the virus and measures viral load in response to therapy. Use in the US will be limited to drug research until the FDA has cleared it for clinical use.